The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First results from the RETgistry: A global consortium for the study of resistance to RET inhibition in RET-altered solid tumors.
 
Alissa Jamie Cooper
Honoraria - MJH Life Sciences
 
Alexander E. Drilon
Stock and Other Ownership Interests - Treeline Biosciences
Honoraria - Answers in CME; Associazione Italiana Oncologia Toracica (AIOT); AstraZeneca; BeiGene; Chugai Pharma; Clinical Care Options/NCCN; Helsinn Therapeutics; i3 Health; IASLC; Ignyta/Genentech/Roche; Liberum; Loxo/Bayer/Lilly; Lung Cancer Research Foundation; Lungevity; NIH; OncLive/MJH Life Sciences; PER; Pfizer; Remedica; Remedica; Research to Practice; RV Mais; Sirio Libanes Hospital; TP Therapeutics; Verastem
Consulting or Advisory Role - 14ner Oncology/Elevation Oncology; Abbvie; Amgen; Applied Pharmaceutical Science; Archer; AstraZeneca; Axis Pharma; Bayer; BeiGene; BerGenBio; Blueprint Medicines; Clinical Care Options; Clinical Care Options; EMD Serono/Merck; Entos; EPG Health; Exelixis; Genentech/Roche; Hengrui Therapeutics; Ignyta; Janssen; Journal of the National Comprehensive Cancer Network; Liberum; Lilly; Loxo; Med Learning; Medscape; Melendi; Merus; Monopteros Therapeutics; Monte Rosa Therapeutics; MORE Health; Novartis; Nuvalent, Inc.; Ology Medical Education; Ology Medical Education; PeerView; Pfizer; Prelude Therapeutics; Repare Therapeutics; Takeda/Millennium; touchIME; Treeline Biosciences; Tyra Biosciences
Research Funding - Foundation Medicine
Patents, Royalties, Other Intellectual Property - Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - Boehringer Ingelheim; GlaxoSmithKline; Merck; Merus; Pfizer; Pfizer; PharmaMar; Puma Biotechnology; Taiho Pharmaceutical; Teva
 
Julia K. Rotow
Honoraria - AstraZeneca
Consulting or Advisory Role - Abbvie; AstraZeneca; Genentech; Gritstone Bio; Guardant Health; Janssen; Lilly; Sanofi/Regeneron; Takeda
Travel, Accommodations, Expenses - AstraZeneca
 
Stephen V. Liu
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Candel Therapeutics; Catalyst Pharmaceuticals; Daiichi Sankyo/UCB Japan; Eisai; Elevation Oncology; Genentech; Gilead Sciences; Guardant Health; Janssen Oncology; Jazz Pharmaceuticals; Merus; MSD Oncology; Novartis; Regeneron; Sanofi; Takeda; Turning Point Therapeutics
Research Funding - Alkermes (Inst); Elevation Oncology (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Merck (Inst); Merus (Inst); Nuvalent, Inc. (Inst); RAPT Therapeutics (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences
 
Oliver Gautschi
Consulting or Advisory Role - Amgen (Inst); Lilly (Inst)
Other Relationship - Bayer (Inst); Lilly; Merck; Pfizer (Inst); Roche (Inst)
 
Katherine Emilie Rhoades Smith
No Relationships to Disclose
 
Dae Ho Lee
Honoraria - Abbvie; AstraZeneca/MedImmune; BC World Pharm; Boehringer Ingelheim; Bristol-Myers Squibb; ChongKeunDang Healthcare; Lilly; Menarini; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche/Genentech; Samyang; ST Cube; Takeda; Yuhan
Consulting or Advisory Role - ST Cube
 
Misako Nagasaka
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences; Daiichi Sankyo; EMD Serono; Genentech; Janssen; Lilly; Mirati Therapeutics; Novartis; Pfizer; Takeda
Speakers' Bureau - Blueprint Medicines; Janssen; Mirati Therapeutics; Mirati Therapeutics; Takeda
Research Funding - Tempus
Travel, Accommodations, Expenses - Anheart Therapeutics
 
Herbert H. F. Loong
Consulting or Advisory Role - Boehringer Ingelheim; Celgene; Eisai; GlaxoSmithKline; Guardant Health; Illumina; Lilly; Novartis; Roche/Genentech; Takeda
Speakers' Bureau - Bayer; Guardant Health; Ignyta; Novartis
Research Funding - MSD Oncology (Inst)
Travel, Accommodations, Expenses - Bayer; MSD Oncology; Pfizer; Roche
 
Nathan A. Pennell
Consulting or Advisory Role - Anheart Therapeutics; Bayer; Genentech; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; Novartis; Pfizer; ResistanceBio; Sanofi/Regeneron; Summit Therapeutics; Takeda; Vial
Research Funding - Anheart Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Loxo (Inst); Merck (Inst); Mirati Therapeutics (Inst); Navire (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst)
 
Jyoti D. Patel
Consulting or Advisory Role - Abbvie; AstraZeneca; Genentech; Lilly; Takeda Science Foundation
Research Funding - Bristol-Myers Squibb (Inst)
 
Martin Früh
Consulting or Advisory Role - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Takeda (Inst)
Research Funding - AstraZeneca (Inst); MSD (Inst)
 
Benjamin J. Solomon
Honoraria - Amgen (Inst); AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche/Genentech
Consulting or Advisory Role - Amgen; AstraZeneca; BeiGene; Bristol-Myers Squibb; GlaxoSmithKline (Inst); Janssen; Lilly; Merck Sharp & Dohme; Novartis (Inst); Pfizer (Inst); Roche/Genentech; Takeda
Research Funding - Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Georg Pall
Consulting or Advisory Role - Amgen; AstraZeneca; BMS GmbH & Co. KG; Boehringer Ingelheim; Daiichi Sankyo Europe GmbH; Janssen Oncology; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Sanofi; Takeda
Speakers' Bureau - Amgen; AstraZeneca; BMS GmbH & Co. KG; Boehringer Ingelheim; Daiichi Sankyo Europe GmbH; Janssen; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Sanofi; Takeda
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; Roche/Genentech
 
Natalie F. Uy
No Relationships to Disclose
 
Jonathan W. Riess
Consulting or Advisory Role - Bayer; BeiGene; Biodesix; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Daiichi Sankyo; EMD Serono; Genentech; Janssen Oncology; Jazz Pharmaceuticals; Merus NV; Novartis; Regeneron; Sanofi; Seagen; Summit pharmaceuticals; Turning Point Therapeutics
Research Funding - ArriVent Biopharma (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Merck (Inst); Novartis (Inst); Revolution Medicines (Inst); Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Lori J. Wirth
Consulting or Advisory Role - Bayer; Coherus Biosciences; Curie Therapeutics; Eisai; Exelixis; Lilly; Merck; METIS Precision Medicine; Morphic Therapeutic; Tome Biosciences
Research Funding - Checkmate Pharmaceuticals (Inst); Eisai (Inst); Lilly (Inst); Novartis (Inst)
Expert Testimony - Eisai
Other Relationship - PDS Biotechnology
 
Beow Y. Yeap
Consulting or Advisory Role - Guardant Health (I)
Research Funding - Mercy BioAnalytics (I)
 
Justin F. Gainor
Employment - Ironwood Pharmaceuticals (I)
Stock and Other Ownership Interests - Ironwood Pharmaceuticals (I)
Honoraria - ARIAD; Incyte; Merck; Novartis; Pfizer; Takeda
Consulting or Advisory Role - Agios; Amgen; Array BioPharma; Blueprint Medicines; Bristol-Myers Squibb; Genentech; Gilead Sciences; ITeos Therapeutics; Jounce Therapeutics; Karyopharm Therapeutics; Lilly; Loxo; Merck; Moderna Therapeutics; Oncorus; Regeneron; Takeda
Research Funding - Adaptimmune (Inst); Alexo Therapeutics (Inst); ARIAD; Array BioPharma (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Genentech; Jounce Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Tesaro (Inst)
 
Jessica Jiyeong Lin
Honoraria - OncLive; Pfizer
Consulting or Advisory Role - Bayer; Blueprint Medicines; C4 Therapeutics; Elevation Oncology; Genentech; Mirati Therapeutics; Novartis; Nuvalent, Inc.; Regeneron; Turning Point Therapeutics
Research Funding - Bayer (Inst); Elevation Oncology (Inst); Hengrui Therapeutics (Inst); Linnaeus Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst); Nuvalent, Inc. (Inst); Relay Therapeutics (Inst); Roche (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Pfizer